News & Press Releases

5 July 2016

Oryzon nominates ORY-3001, a specific LSD1 inhibitor, next drug candidate to enter preclinical development in non-oncological indications

6 June 2016

ORYZON to Present at the JMP Securities Life Sciences Conference on June 22nd, 2016

2 June 2016

EpigenomicsNet features Oryzon CSO Tamara Maes on Epigenetic drug development

18 May 2016

ORYZON to extend its R&D collaboration on ORY-1001 until March 2017

12 May 2016

ORYZON Reports First Quarter 2016 Financial Results and Corporate Update

4 May 2016

ORYZON Closes € 10.5 Million (12.1 M USD) Debt Financing

11 April 2016

Data on ORY-1001 to Be Presented at the AACR Annual Meeting 2016 in New Orleans

4 April 2016

ORYZON Announces First Subject Dosed in Phase I Healthy Volunteer Study Evaluating Oral Epigenetic drug ORY-2001 for Alzheimer’s Disease

23 February 2016

Oryzon to Attend the 36th Annual Cowen Health Care Conference

16 February 2016

Oryzon Genomics Announces Presentation and Panel Discussion at the SACHS Associates 1st Annual Neuroscience BioPartnering & Investment Forum

News